Information  X 
Enter a valid email address

Company Name matching 'ObsEva SA'

Date
Time Source
Company
Announcement
01 Aug 2022 12:00 pm GNW   ObsEva SA ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing
29 Jul 2022 6:00 am GNW   ObsEva SA ObsEva Announces Management Change
27 Jul 2022 6:00 am GNW   ObsEva SA ObsEva Announces Corporate Updates
  5:55 am GNW   ObsEva SA ObsEva Announces Corporate Updates
28 Jun 2022 9:01 pm GNW   ObsEva SA ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
17 Jun 2022 6:00 am GNW   ObsEva SA ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
27 May 2022 9:01 pm GNW   ObsEva SA ObsEva Announces Corporate Updates
25 May 2022 6:00 am GNW   ObsEva SA ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses
19 May 2022 6:05 am GNW   ObsEva SA ObsEva Announces Appointment of Annette Clancy as Chair of the Board of Directors
  6:00 am GNW   ObsEva SA ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2022 Annual General Meeting held on May 18, 2022
17 May 2022 6:00 am GNW   ObsEva SA ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update
16 May 2022 6:00 am GNW   ObsEva SA ObsEva to Present at the H.C. Wainwright Global Investment 2022 Conference
12 May 2022 6:00 am GNW   ObsEva SA ObsEva to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update
09 May 2022 6:00 am GNW   ObsEva SA ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at the 2022 ACOG Annual Clinical and Scientific Meeting
02 May 2022 6:00 am GNW   ObsEva SA ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer
25 Apr 2022 6:00 am GNW   ObsEva SA ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
07 Apr 2022 6:00 am GNW   ObsEva SA ObsEva Annual General Meeting 2022
31 Mar 2022 6:00 am GNW   ObsEva SA ObsEva Annual Report 2021
22 Mar 2022 11:00 am GNW   ObsEva SA ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
  6:00 am GNW   ObsEva SA ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
10 Mar 2022 6:00 am GNW   ObsEva SA ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update
10 Feb 2022 9:11 pm GNW   ObsEva SA ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
04 Feb 2022 9:15 pm GNW   ObsEva SA ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
01 Feb 2022 6:00 am GNW   ObsEva SA ObsEva Appoints Katja Buhrer as Chief Strategy Officer
28 Jan 2022 9:01 pm GNW   ObsEva SA ObsEva Announces Corporate Updates
06 Jan 2022 6:00 am GNW   ObsEva SA ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
03 Jan 2022 6:00 am GNW   ObsEva SA ObsEva to Present at the H.C. Wainwright BioConnect 2022 Conference
20 Dec 2021 6:00 am GNW   ObsEva SA ObsEva Added to the NASDAQ Biotechnology Index
17 Dec 2021 6:00 am GNW   ObsEva SA ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
13 Dec 2021 6:00 am GNW   ObsEva SA ObsEva Appoints Will Brown as Chief Financial Officer
10 Dec 2021 6:00 am GNW   ObsEva SA ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021
02 Dec 2021 6:00 am GNW   ObsEva SA ObsEva Announces Symposium and Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021
22 Nov 2021 6:05 am GNW   ObsEva SA Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
  6:00 am GNW   ObsEva SA Obseva Announces Appointment of Stephanie Brown to its Board of Directors
04 Nov 2021 6:00 am GNW   ObsEva SA ObsEva Announces Third Quarter 2021 Financial Results and Business Update
29 Oct 2021 9:30 pm GNW   ObsEva SA ObsEva Announces Management Change
20 Oct 2021 6:00 am GNW   ObsEva SA ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at ASRM 2021 Scientific Congress & Expo
19 Oct 2021 6:00 am GNW   ObsEva SA ObsEva Announces Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at ASRM 2021 Scientific Congress & Expo
13 Oct 2021 6:00 am GNW   ObsEva SA ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
30 Sep 2021 6:00 am GNW   ObsEva SA ObsEva Announces Appointment of Luigi Marro as Chief Transformation Officer
15 Sep 2021 6:00 am GNW   ObsEva SA ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids
07 Sep 2021 6:00 am GNW   ObsEva SA ObsEva to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
05 Aug 2021 6:00 am GNW   ObsEva SA ObsEva Announces Second Quarter 2021 Financial Results and Business Update
04 Aug 2021 6:00 am GNW   ObsEva SA ObsEva Announces Two Cornerstone Publications Describing Clinical Trials of Nolasiban for Improving Pregnancy and Live Birth Outcomes Following IVF
03 Aug 2021 6:00 am GNW   ObsEva SA ObsEva to Present at Upcoming Investor Conferences
27 Jul 2021 6:00 am GNW   ObsEva SA Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor
02 Jul 2021 6:00 am GNW   ObsEva SA ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting
30 Jun 2021 6:00 am GNW   ObsEva SA ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty® (linzagolix) for the Treatment of Severe Adenomyosis at ESHRE Virtual 37th Annual Meeting
24 Jun 2021 6:00 am GNW   ObsEva SA ObsEva To Present Data on Two Clinical Development Programs at ESHRE Virtual 37th Annual Meeting
10 Jun 2021 6:00 am GNW   ObsEva SA ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022) for the Treatment of Spontaneous Preterm Labor at the RCOG Virtual World Congress 2021
02 Jun 2021 6:00 am GNW   ObsEva SA ObsEva Announces Oral Presentation at the RCOG Virtual World Congress 2021
31 May 2021 6:00 am GNW   ObsEva SA ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2021 Annual General Meeting held on May 28, 2021
25 May 2021 9:05 pm GNW   ObsEva SA ObsEva Announces Proposed Changes to the Composition of its Board of Directors
20 May 2021 6:00 am GNW   ObsEva SA ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
06 May 2021 6:00 am GNW   ObsEva SA ObsEva Announces First Quarter 2021 Financial Results and Business Update
  5:55 am GNW   ObsEva SA ObsEva appoints Clive Bertram as Chief Commercial Officer
04 May 2021 6:00 am GNW   ObsEva SA ObsEva Announces Enrollment Completion of Linzagolix Phase 3 EDELWEISS 3 Trial for Patients with Moderate to Severe Endometriosis-Associated Pain
30 Apr 2021 9:05 pm GNW   ObsEva SA ObsEva SA presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 - May 2, 2021
27 Apr 2021 6:00 am GNW   ObsEva SA ObsEva Initiates PRIMROSE 3 Bone Mineral Density Follow-Up Study in PRIMROSE 1 and PRIMROSE 2 Trial Participants
22 Apr 2021 6:00 am GNW   ObsEva SA ObsEva Annual General Meeting 2021


Company Announcements Archive »


a d v e r t i s e m e n t